Kinney Horn - Jan 10, 2022 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role: CHIEF BUSINESS OFFICER
Signature: /s/ John B. Moriarty, Jr., Attorney-in-Fact
Stock symbol: OLMA
Transactions as of: Jan 10, 2022
Transactions value $: -$25,131
Form type: 4
Date filed: 1/11/2022, 07:21 PM
Previous filing: Dec 14, 2021
Next filing: Feb 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OLMA	Common Stock	Options Exercise	$10.8K	+5.25K	+213.63%	$2.06^*	7.71K	Jan 10, 2022	Direct
transaction	OLMA	Common Stock	Sale	-$36K	-5.25K	-68.12%	$6.85	2.46K	Jan 10, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OLMA	Stock Option (Right to Buy)	Options Exercise	$0	-5.25K	-3.33%	$0.00	152K	Jan 10, 2022	Common Stock	5.25K	$2.06	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2	The weighted average sale price for the transaction reported was $6.85, and the range of prices were between $6.60 and $7.22. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3	The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.